FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Metastatic Cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : New treatment option for advanced or recurrent endometrial cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with advanced or recurrent endometrial cancer
If you have advanced or recurrent endometrial cancer, there is a new treatment called Jemperli (dostarlimab) that could be an option for you. This study looked at how well Jemperli worked compared to standard treatment. Based on these results, the Food and Drug Administration (FDA) approved the combination of Jemperli and chemotherapy for certain types of advanced endometrial cancer. (Posted 8/4/23)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Breast cancer outcomes improved with CDK4/6 inhibitor treatment
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People with HR-positive HER2-negative advanced breast cancer
A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : New oral drug treatment for some advanced breast cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with HR-positive, HER2-negative advanced breast cancer
The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Promising early results for treating metastatic prostate cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with metastatic castration-resistant prostate cancer (mCRPC)
The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)
Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage.
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Trodelvy benefits people with advanced hormone-positive metastatic breast cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with ER/PR-positive, HER2-negative metastatic breast cancer
The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)
Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Promising early results for people with DNA mismatch repair deficient rectal cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with rectal cancer with high mutational burden or mismatch repair problems including people with Lynch syndrome.
A small research study tested the usefulness of the immunotherapy drug dostarlimab for treating locally advanced rectal cancer with a biomarker known as “dMMR” (DNA mismatch repair deficient). None of the participants had evidence of cancer six months later; some remained cancer free for up to 25 months). Many participants had Lynch syndrome. The remarkable response to this treatment may allow people with this particular subtype of rectal cancer to avoid potentially life-changing rectal surgery. (Posted 11/14/22) Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Study : More is not better: PARP dose can be safely reduced for people with ovarian cancer
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People taking a PARP inhibitor for ovarian cancer maintenance therapy
Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)
Este artículo está disponible en español.
Read More
Update : Strategies for managing pancreatic cancer pain
Most relevant for: People with pancreatic cancer who are dealing with related pain.
Abdominal pain is often a severe, ongoing symptom of pancreatic cancer, yet little research has been done on how to best reduce this pain. The authors of this review discuss current strategies for managing cancer-related pain and their effectiveness. (Posted 10/31/22)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Acupuncture may ease breast cancer treatment side effects
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People considering acupuncture for managing breast cancer treatment symptoms.
Acupuncture can ease some symptoms of breast cancer treatment. Multiple studies found that acupuncture is a safe and effective strategy to manage certain symptoms but also called for more rigorous research on the topic. (Posted 9/28/22) Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Study : Expanding Medicaid reduced racial disparities among people with metastatic breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: People diagnosed with de novo stage 4 breast cancer and people who live in states that have not expanded Medicaid.
The Affordable Care Act allowed more people to access insurance through Medicaid. This study found the expansion of care improved survival and decreased mortality among people of color with de novo stage 4 (stage 4 at the time of initial diagnosis) breast cancer. (Posted 9/13/2022). Este artículo está disponible en español.
Read More